Evolent Health (EVH) Gains from Investment Securities (2015 - 2026)

Evolent Health's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 60.46% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $10.4 million (up 196.76% YoY), while the FY2025 annual figure was $6.5 million, up 3708.33% from the prior year.
• Gains from Investment Securities was $1.8 million for Q1 2026 at Evolent Health, down from $6.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $14.3 million in Q1 2024 to a low of -$40.9 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged -$1.5 million across 5 years, with a median of $1.3 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities plunged 51276.25% in 2022, then surged 25496.43% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$40.9 million in 2022, then soared by 114.5% to $5.9 million in 2023, then slumped by 362.25% to -$15.6 million in 2024, then jumped by 141.71% to $6.5 million in 2025, then slumped by 72.04% to $1.8 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.8 million (Q1 2026), $6.5 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.